Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.
Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC. Gomez-Roca CA, et al. Among authors: angevin e. Ann Oncol. 2012 May;23(5):1301-1306. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14. Ann Oncol. 2012. PMID: 21917737 Free article.
Dendritic cell-based immunotherapy of cancer.
Zitvogel L, Angevin E, Tursz T. Zitvogel L, et al. Among authors: angevin e. Ann Oncol. 2000;11 Suppl 3:199-205. doi: 10.1093/annonc/11.suppl_3.199. Ann Oncol. 2000. PMID: 11079142 Free article. Review. No abstract available.
Phase II trial of thalidomide in renal-cell carcinoma.
Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A. Escudier B, et al. Among authors: angevin e. Ann Oncol. 2002 Jul;13(7):1029-35. doi: 10.1093/annonc/mdf213. Ann Oncol. 2002. PMID: 12176780 Free article. Clinical Trial.
Exosomes for cancer immunotherapy.
Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L. Andre F, et al. Among authors: angevin e. Ann Oncol. 2004;15 Suppl 4:iv141-4. doi: 10.1093/annonc/mdh918. Ann Oncol. 2004. PMID: 15477298 Free article. Review. No abstract available.
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C. Escudier B, et al. Among authors: angevin e. Clin Cancer Res. 2007 Mar 15;13(6):1801-9. doi: 10.1158/1078-0432.CCR-06-1432. Clin Cancer Res. 2007. PMID: 17363536 Clinical Trial.
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B. Kossai M, et al. Among authors: angevin e. Lung Cancer. 2015 Sep;89(3):306-10. doi: 10.1016/j.lungcan.2015.06.014. Epub 2015 Jun 22. Lung Cancer. 2015. PMID: 26160757
104 results